Clinical trial of CA002 peanut allergy immunotherapy in children

花生过敏是儿童和成人中最常见的严重反应和食物过敏死亡原因。管理这些风险的持续需要大大降低了过敏患者及其家人的生活质量。Camallergy率先开发了一种新型生物口服免疫治疗药物CA002，用于治疗花生过敏，以保护患者在不小心食用含有花生的食物时免受严重反应。它的目标是在开始治疗的12周内提供保护，显著提高生活质量。该治疗方案通过逐渐暴露于越来越多的特征性过敏原蛋白来使患者脱敏，包括7次短期治疗就诊和2年简单的每日给药。剑桥花生过敏诊所（CPAC）的早期接触项目在200多名儿童中取得了95%的成功。该项目将在英国和爱尔兰进行三期临床试验，旨在确认CA002在CPAC上的成功，定位CA002在英国和国际上用于儿童和成人的批准。

Peanut allergy is the most common cause of severe reactions and food allergy deaths in children and adults. The continuous need to manage these risks profoundly reduces quality of life of allergy sufferers and their families.Camallergy is pioneering a novel biological oral immunotherapy drug CA002 for the treatment of peanut allergy to protect patients from severe reactions should they accidentally eat food containing peanut. It aims to provide protection within 12 weeks of starting treatment, significantly improving quality of life. The treatment regime desensitises patients by gradual exposure to increasing amounts of characterised allergenic proteins and involves seven short treatment visits and two years of easy, daily administration. The early access programme at Cambridge Peanut Allergy Clinic (CPAC) has achieved \>95% success in over 200 children. This project will conduct a Phase 3 clinical trial in the UK and Ireland, designed to confirm the success of CA002 at CPAC, positioning CA002 for approval for use in children and adults in the UK and internationally.